NDC properties for NDC 9 54436-250
NDC item 54436025001
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-01 |
| NDC Item | 54436025001 |
| packaging | 1 SYRINGE in 1 CARTON (54436-250-01) / .5 mL in 1 SYRINGE (54436-250-03) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
NDC item 54436025002
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-02 |
| NDC Item | 54436025002 |
| packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
NDC item 54436025003
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-03 |
| NDC Item | 54436025003 |
| packaging | 0.5 mL in 1 SYRINGE |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |
NDC item 54436025004
| NDC 9 | 54436-250 |
|---|---|
| NDC 10 | 54436-250-04 |
| NDC Item | 54436025004 |
| packaging | 4 SYRINGE in 1 CARTON (54436-250-04) / .5 mL in 1 SYRINGE (54436-250-02) |
| DCSA | CIII |
| FDA SPL set id | 860412 |
| Labeler | Antares Pharma, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-11-15 |
| Marketing status | ACTIVE |
| NDA | NDA209863 |